[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![dg_fit61882 Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1888599248654233600.png) PaganoCapital [@dg_fit61882](/creator/twitter/dg_fit61882) on x XX followers
Created: 2025-07-26 18:57:12 UTC

Bright Minds Biosciences ($DRUG) trades at ~$35.46, giving it a market cap of ~$250M with just 7.08M shares outstanding (73–75% institutional ownership)  . 

Its lead molecule, BMB‑101, is now in an open-label Phase X trial for absence epilepsy & DEE after XXX% seizure survival in SUDEP mouse models  . 

TD Cowen and Chardan initiated Buy coverage with price targets in the $80–$92 range  . 

Highly selective 5‑HT2C agonist designed to minimize tolerance via Gq pathway activation. Phase X depends on upcoming data. 
#Biotech #Epilepsy #CNS #Microcap


XX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1949182232171855923/c:line.svg)

**Related Topics**
[market cap](/topic/market-cap)
[250m](/topic/250m)
[stocks](/topic/stocks)
[$250m](/topic/$250m)
[$drug](/topic/$drug)
[minds](/topic/minds)

[Post Link](https://x.com/dg_fit61882/status/1949182232171855923)